Estrone (E1) Medication-Driven Changes: Normal Range, Optimal Levels, and Clinical Interpretation

What Is Estrone (E1) and Why Does It Matter?

Estrone is the weakest of the three primary human estrogens, but it becomes the most abundant one after menopause. Its relative potency at the estrogen receptor is roughly one-third that of estradiol (E2) and far greater than estriol (E3). Because adipose tissue is the dominant post-menopausal factory for E1, body-composition changes, weight loss drugs, and any medication that modifies aromatase activity will move E1 levels on a lab panel.

Biosynthesis Pathway

The adrenal glands secrete androstenedione, which peripheral aromatase (CYP19A1) converts to estrone in fat cells, skin, and liver. In premenopausal women, the ovaries also secrete E1 directly. After menopause, ovarian secretion drops to near zero and adipose aromatization accounts for roughly 95% of circulating E1 [1].

Interconversion With Estradiol

E1 and E2 interconvert continuously through 17-beta-hydroxysteroid dehydrogenase (17-beta-HSD). This bidirectional exchange means that measuring E1 alone without E2 gives an incomplete picture. The E1:E2 ratio is a practical tool: a ratio consistently above 2:1 in a woman on hormone therapy may indicate a hepatic first-pass effect from oral dosing rather than balanced systemic estrogen delivery [2].

Why Low E1 Is Not Always Desirable

Some clinicians assume lower estrogen is always safer in postmenopausal women. The data do not support that position uniformly. The Women's Health Initiative Memory Study showed that estrogen-alone therapy in women aged 65 to 79 did not increase dementia risk when initiated in the early postmenopausal window [3]. Chronically suppressed E1 in older women correlates with lower bone mineral density and higher fracture rates [4].

Normal and Optimal Estrone Ranges by Life Stage

Knowing a patient's life stage, menstrual status, and current medications is mandatory before interpreting any E1 result. A value of 25 pg/mL is reassuring in a naturally postmenopausal woman not using HRT but would signal significant under-replacement in a 52-year-old on transdermal estradiol with hot flashes.

Premenopausal Reference Ranges

| Phase | Typical E1 Range (pg/mL) | |---|---| | Early follicular | 17 to 80 | | Mid-cycle (periovulatory) | 100 to 200 | | Luteal | 40 to 170 | | Pregnancy (first trimester) | 300 to 2,000 |

Values vary significantly across assay platforms. The Endocrine Society's 2023 clinical practice guidelines on female hypogonadism recommend LC-MS/MS over immunoassay for values below 50 pg/mL due to immunoassay cross-reactivity with other steroids [5].

Postmenopausal Reference Ranges

In the absence of exogenous hormones, most postmenopausal women maintain E1 between 7 and 40 pg/mL [1]. Obesity shifts this range upward because greater adipose mass means more aromatase substrate and enzymatic capacity. One cross-sectional analysis of 587 postmenopausal women found that those with a BMI above 30 kg/m² had median E1 values of 48 pg/mL compared with 21 pg/mL in normal-weight counterparts (P<0.001) [6].

HealthRX Functional Target on HRT

The HealthRX medical team applies a working functional target of 40 to 115 pg/mL for E1 in postmenopausal women receiving hormone replacement therapy, layered on top of an E2 target of 50 to 150 pg/mL. These are not rigid thresholds. They are starting points for a shared clinical conversation about symptom burden, bone turnover markers, and individual risk tolerance. Women with a personal or strong family history of estrogen-receptor-positive breast cancer may benefit from tighter targets, calibrated alongside an oncologist.

How Specific Medications Shift Estrone Levels

This section is the core clinical content. Each drug class produces a distinct and predictable pattern on the E1 panel. Recognizing those patterns allows for smarter dosing decisions without chasing numbers that are moving for mechanistic, not pathological, reasons.

Oral Estradiol

Oral estradiol (available generically; brand names include Estrace) undergoes extensive hepatic first-pass metabolism. The intestinal mucosa and liver convert a substantial portion of the absorbed dose to estrone and estrone sulfate before the hormone reaches the systemic circulation [2].

In a pharmacokinetic crossover study comparing 2 mg oral estradiol with 0.05 mg/day transdermal estradiol in 24 postmenopausal women, oral dosing produced an E1:E2 molar ratio of approximately 5:1, whereas transdermal delivery maintained a ratio closer to 1.3:1 [7]. The total E1 exposure (area under the curve) was roughly four times higher with oral dosing at equivalent estradiol doses.

Clinical implication: A high E1 reading in a woman on oral estradiol does not necessarily mean she is over-replaced. It reflects route-of-administration pharmacology. Before increasing the dose based on low E2 alone, check the E1:E2 ratio. If E1 is already elevated, switching to transdermal or vaginal delivery may correct both the ratio and the E2 level without adding total estrogen load [7].

Transdermal Estradiol

Patches, gels, and sprays deliver estradiol directly to the systemic circulation, bypassing the portal hepatic circulation. The resulting E1:E2 ratio more closely mirrors the premenopausal physiology. Standard doses of 0.05 to 0.1 mg/day transdermal estradiol typically produce E1 levels in the 40 to 90 pg/mL range and E2 levels of 50 to 100 pg/mL [8].

Transdermal delivery also avoids the hepatic induction of sex-hormone-binding globulin (SHBG) and coagulation proteins seen with oral estrogen. This distinction has clinical significance. The ESTHER study (N=881) showed that transdermal but not oral estrogen was associated with a neutral risk profile for venous thromboembolism in postmenopausal women [9].

Subcutaneous Estradiol Pellets

Pellet implants produce sustained estradiol release over 3 to 6 months. Because the dose is fixed at insertion, E1 levels can fluctuate widely depending on the insertion cycle phase. Early in the cycle, E1 and E2 may run higher than target; near the end, both may drop below replacement range. Monthly monitoring during the first two cycles helps characterize the individual pharmacokinetic curve.

Aromatase Inhibitors

Aromatase inhibitors (AIs) block CYP19A1, the enzyme that converts androgens to estrogens. Used in postmenopausal women with hormone-receptor-positive breast cancer, they suppress E1 with remarkable efficiency.

In the ATAC trial (N=9,366), anastrozole 1 mg/day reduced circulating E1 by approximately 87% compared with baseline, with similar suppression seen with letrozole 2.5 mg/day in the BIG 1-98 trial (N=8,010) [10, 11]. Exemestane, a steroidal AI, achieves comparable E1 suppression of roughly 85%.

Monitoring on AIs: E1 values below 5 pg/mL are expected and goal-consistent in this population. Paradoxically elevated E1 on AI therapy may indicate non-adherence, drug interactions, or a significant increase in adipose aromatase substrate. The American Society of Clinical Oncology guideline (2022) recommends annual bone mineral density testing in all postmenopausal women initiating adjuvant AI therapy, given that profound estrogen suppression accelerates bone resorption [12].

Selective Estrogen Receptor Modulators (SERMs)

SERMs (tamoxifen, raloxifene, ospemifene, bazedoxifene) do not meaningfully change circulating E1 concentrations because they act at the receptor level, not at the synthesis level. In premenopausal women, tamoxifen may actually increase E1 slightly by disrupting negative feedback on the hypothalamic-pituitary-ovarian axis, leading to higher gonadotropin stimulation and greater ovarian steroidogenesis [13].

The clinical takeaway: a normal or even elevated E1 in a woman on tamoxifen is expected. It does not mean the therapy is failing. The protective effect comes from receptor blockade at breast tissue, not from estrogen suppression per se.

GLP-1 Receptor Agonists

This connection is underappreciated in everyday clinical practice. GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide) produce meaningful weight loss, and adipose tissue is the primary postmenopausal estrone factory. Reducing fat mass reduces aromatase-available substrate, and E1 levels drop as a secondary effect.

In STEP-1 (N=1,961), semaglutide 2.4 mg once weekly produced a mean weight loss of 14.9% at 68 weeks versus 2.4% in the placebo group (P<0.001) [14]. Modeling from cross-sectional adipose-aromatase data suggests that a 15% reduction in fat mass could lower E1 by 10 to 20% in a postmenopausal woman, though prospective E1-specific data from GLP-1 trials are not yet published.

Practical monitoring point: Postmenopausal women initiating a GLP-1 agonist should have E1 (and E2 if on HRT) rechecked at 3 and 6 months. A woman previously well-controlled on HRT may develop recurrent vasomotor symptoms as weight loss progresses, requiring an upward dose adjustment, not a change in medication class.

Progesterone and Progestogens

Neither micronized progesterone nor synthetic progestins (medroxyprogesterone acetate, norethindrone acetate) alter E1 synthesis directly. They may, however, reduce peripheral conversion of androgens to estrogens at high concentrations by competing for 17-beta-HSD activity, producing a small, generally clinically insignificant decrease in E1 in some women [15].

The more relevant interaction is with oral combination HRT. A preparation that combines oral estradiol with a progestin will still produce the high-E1 oral-first-pass pattern. Switching to a combination patch (e.g., estradiol plus norethindrone acetate transdermal system) corrects the ratio.

Testosterone Therapy in Women and Transgender Men

Testosterone therapy is prescribed off-label in cisgender women for low libido and in transgender men (assigned female at birth) as affirming hormone therapy. Testosterone is a direct aromatase substrate. Supraphysiologic or even high-physiologic testosterone levels significantly raise E1 through aromatization in adipose and muscle tissue [16].

In transgender men receiving testosterone injections (typically testosterone cypionate 50 to 100 mg IM every 1 to 2 weeks), circulating E1 may remain measurable and even elevated relative to pre-treatment baseline during the early months of therapy before ovarian suppression is complete. Ongoing E1 monitoring helps confirm adequate suppression, which typically reaches postmenopausal-equivalent levels within 6 to 12 months of consistent testosterone therapy [16].

Androgen-Deprivation Therapy in Men

Men are often overlooked in discussions of E1, but they carry measurable circulating estrone produced by aromatization of testosterone and adrenal androgens. In prostate cancer patients on GnRH agonist therapy (leuprolide, goserelin) or GnRH antagonist therapy (degarelix, relugolix), testosterone falls to castrate levels (<50 ng/dL), and E1 drops in parallel. Mean E1 in men on ADT runs 5 to 15 pg/mL, compared with 10 to 40 pg/mL in eugonadal men [17]. This suppression accelerates trabecular bone loss at a rate of 2 to 3% per year, supporting routine DEXA monitoring every 1 to 2 years on long-term ADT per AUA guidelines.

Interpreting E1 in the Context of the Full Hormone Panel

Estrone results do not live in isolation. The following contextual checks improve clinical accuracy.

E1:E2 Ratio

A ratio above 2.5 in a woman on any oral estrogen product is expected pharmacology. A ratio above 2.5 in a woman on transdermal estrogen only may suggest exogenous source questions (e.g., hidden oral intake, compounded preparations) or impaired E1 clearance from liver dysfunction.

E1 and SHBG

High-dose oral estrogen drives SHBG synthesis in the liver. Elevated SHBG then binds more estradiol, lowering free E2 even when total E2 appears adequate. In this scenario, E1 can be high, total E2 moderate, and free E2 low, explaining persistent menopausal symptoms despite seemingly adequate hormone levels on standard panels.

E1 Sulfate as a Reservoir

Estrone sulfate (E1S) is the most abundant circulating estrogen in postmenopausal women, present at concentrations 5 to 10 times higher than free E1. Sulfotransferase and sulfatase enzymes interconvert E1 and E1S, creating a long-lived peripheral reservoir. This reservoir means that even after stopping oral estrogen, free E1 may remain detectable for several weeks as E1S is hydrolyzed back to free estrone [2].

Laboratory Measurement: Immunoassay vs. LC-MS/MS

The choice of assay platform materially affects how to interpret a result, particularly at the lower end of the postmenopausal range.

Immunoassay

Standard immunoassay platforms are widely available and inexpensive, but they cross-react with estrone sulfate, estriol, and other steroids at low concentrations. Below 20 pg/mL, coefficient of variation for immunoassay E1 can exceed 25% in inter-assay comparisons. This is clinically meaningful when monitoring AI therapy where suppression to single-digit values is the goal.

LC-MS/MS

Liquid chromatography-tandem mass spectrometry offers specificity and sensitivity that immunoassay cannot match. The Endocrine Society's 2023 position statement on sex-steroid measurement states: "LC-MS/MS should be the preferred method for measuring estradiol, estrone, and other steroid hormones, particularly when concentrations are low or clinical decisions depend on accurate measurement" [5].

HealthRX orders LC-MS/MS-based panels as the default for all postmenopausal hormone monitoring. When interpreting results from an outside lab, confirm the assay method before comparing values longitudinally across platforms.

Clinical Decision Framework: When to Retest E1

The following schedule applies to HealthRX patients on hormone replacement therapy, based on pharmacokinetic data and clinical stability endpoints:

• Baseline: Before initiating or changing any hormone therapy.
• 4 to 6 weeks after dose change: Oral estradiol reaches new steady-state within 2 weeks; transdermal patches reach steady-state within 3 to 4 days, but symptom assessment lags 4 weeks.
• Every 6 months (stable patients): Hormone levels can shift with weight change, aging, and medications added for unrelated conditions.
• Any time symptoms change: New hot flashes, breast tenderness, or mood changes on an established regimen warrant an unscheduled panel before adjusting doses empirically.
• 3 and 6 months after starting a GLP-1 agonist: As discussed, weight-loss-driven E1 suppression can unmask relative under-replacement.

Safety Considerations: When High E1 Raises Concern

Chronically elevated E1, outside the expected range for route of administration or body-composition context, deserves investigation.

Estrogen-Receptor-Positive Breast Cancer Risk

The Nurses' Health Study (N=32,826 postmenopausal women followed 10 years) found that women in the highest quartile of circulating E1 had a relative risk of 2.0 for ER-positive breast cancer compared with the lowest quartile [18]. Absolute risk remained low, but this association supports measuring E1 rather than only E2 in breast cancer risk conversations.

Endometrial Hyperplasia

Unopposed estrone in postmenopausal women with an intact uterus drives endometrial proliferation. Any postmenopausal woman with an intact uterus on estrogen therapy requires concomitant progestogen or progestin coverage. The American College of Obstetricians and Gynecologists recommends that combined (estrogen plus progestogen) therapy is mandatory in this group to reduce the risk of endometrial cancer [19].

Adrenal or Ovarian Estrogen-Secreting Tumors

A postmenopausal woman not on any exogenous estrogen with E1 above 60 pg/mL warrants evaluation for an estrogen-secreting tumor. Granulosa cell tumors of the ovary are the most common cause. Transvaginal ultrasound and an inhibin B level are first-line investigative tools in this scenario.